stockrow
Friday 6 November 2026
Export CNXU’s income statement to Excel — free account
Conexeu Sciences Inc.
CNXU Healthcare Biotechnology
- EPS
- −214.9%
- Free cash flow
- −1,084.3%
Quarter to July 2026, against a year earlier
2.09
0.13
−5.86%
Follow CNXU
Alert me
| Older periods | Oct '25 | Jan '26 | Apr '26 | Jul '26 | |
|---|---|---|---|---|---|
Current Ratio |
+4 more quarters Free account |
22.20 | 18.51 | 14.93 | 5.31 |
Net Debt/EBITDA |
2.59 | 3.91 | 3.08 | 0.29 | |
Debt/Assets |
0.00% | 0.00% | 0.00% | 0.00% | |
Debt/Equity |
0.00 | 0.00 | 0.00 | 0.00 | |
Asset Turnover |
0.00 | 0.00 | 0.00 | 0.00 | |
Operating CF/Net income |
0.23 | 0.89 | 0.78 | 0.87 | |
Capex/Depreciation |
0.00 | (0.73) | (2.62) | (7.67) | |
Interest Coverage |
18,742.00 | — | — | — | |
Research and Development Expense of Revenue |
0.00% | 0.00% | 0.00% | 0.00% | |
Selling, General and Administrative Expense of Revenue |
0.00% | 0.00% | 0.00% | 0.00% | |
Intangible Assets out of Total Assets |
0.02 | 0.02 | 0.02 | 0.02 | |
Free Cash Flow per Share |
(0.03) | (0.08) | (0.09) | (0.25) | |
Cash per Share |
0.38 | 0.33 | 0.36 | 0.08 | |
Shareholders Equity per Share |
0.58 | 0.34 | 0.35 | 0.22 | |
Interest Debt per Share |
0.00 | 0.00 | 0.00 | 0.00 | |
Book value per Share |
0.58 | 0.34 | 0.35 | 0.22 | |
Free Cash Flow |
(0.43) | (1.54) | (1.83) | (6.80) | |
Working Capital |
7.12 | 7.06 | 7.38 | 5.48 | |
Capital Expenditures |
0.00 | 0.00 | (0.03) | (0.04) | |
Net Current Asset Value |
7.12 | 6.58 | 6.91 | 5.45 | |
| Other line items | |||||
Quick Ratio |
20.35 | 16.65 | 13.78 | 1.74 | |
Revenue per Share |
0.00 | 0.00 | 0.00 | 0.00 | |
Operating CF per Share |
(0.03) | (0.08) | (0.09) | (0.25) | |
Capex per Share |
0.00 | 0.00 | 0.00 | 0.00 | |
Average Payables |
— | — | — | 0.58 | |
Average Assets |
4.11 | 3.85 | 4.10 | 3.85 | |
Average Common Equity |
— | — | — | 2.97 | |
Capex to Sales |
0.00 | 0.00 | 0.00 | 0.00 |
Columns are period end dates · fundamentals updated 2 Nov 2026